Product Information

MOMETASONE FUROATE 50 MCG SPRY is a generic product labeled by Aurobindo Pharma Limited, priced at $1.5635 per GM under NDC 59651040217. Its NADAC has been published 119 times since Aug 7, 2024.

FDA first approved this application on Mar 18, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

MOMETASONE FUROATE 50 MCG SPRY

MOMETASONE FUROATE MONOHYDRATE
$1.5635per GM

Strength

50 ug/1

NDC

59651040217

Classification

Generic

Dosage Form

SPRAY, METERED

Route

NASAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA215878

FDA Approved

3/18/2024

TE Code

AB

On Market Since

3/18/2024

Pharmacological Classes

Corticosteroid Hormone Receptor Agonists
Corticosteroid Hormone Receptor Agonists
Corticosteroid

Price Statistics

The NADAC for MOMETASONE FUROATE 50 MCG SPRY has been published 119 times since Aug 7, 2024, and over the history we have for it it has declined 28.3%. The table below summarizes its recorded NADAC range and movement.

Current price$1.5635 per GM
All-time high$2.1803 (Aug 14, 2024)
All-time low$1.5635 (Oct 21, 2026)
52-week high$1.7874
52-week low$1.5635
Median price$1.7270
Average price$1.7346
Largest weekly change-14.3% (Nov 20, 2024)
Weeks tracked119
Tracking sinceAug 7, 2024

Price History

1W

0.0%

1M

-1.5%

3M

-2.6%

6M

-2.7%

1Y

-9.9%

3Y

N/A

5Y

N/A

All

-28.3%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the MOMETASONE FUROATE MONOHYDRATE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of MOMETASONE FUROATE 50 MCG SPRY?

The current National Average Drug Acquisition Cost (NADAC) for MOMETASONE FUROATE 50 MCG SPRY, manufactured by Aurobindo Pharma Limited, is $1.5635 per GM (NDC 59651040217), effective Nov 11, 2026.

How has the price of MOMETASONE FUROATE 50 MCG SPRY changed over time?

Over the history we have for it, the NADAC for MOMETASONE FUROATE 50 MCG SPRY has declined 28.3%. It has been tracked across 119 weekly CMS publications since Aug 7, 2024.

What are the highest and lowest recorded NADAC prices for MOMETASONE FUROATE 50 MCG SPRY?

Since Aug 7, 2024, the NADAC for MOMETASONE FUROATE 50 MCG SPRY has ranged from a low of $1.5635 (Oct 21, 2026) to a high of $2.1803 (Aug 14, 2024), with a median of $1.7270 per GM.

Are there cheaper alternatives to MOMETASONE FUROATE 50 MCG SPRY?

No other NADAC-published product currently shares the active ingredient and strength of MOMETASONE FUROATE 50 MCG SPRY in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures MOMETASONE FUROATE 50 MCG SPRY?

MOMETASONE FUROATE 50 MCG SPRY (NDC 59651040217) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.